Immunotherapy for patients with malignant glioma: from theoretical principles to clinical applications.
Malignant gliomas are the most common type of primary brain tumor and are in great need of novel therapeutic approaches. Advances in treatment have been very modest, significant improvement in survival has been lacking for many decades and prognosis remains dismal. Despite 'gross total' surgical resections and currently available radio-chemotherapy, malignant gliomas inevitably recur due to reservoirs of notoriously invasive tumor cells that infiltrate adjacent and nonadjacent areas of normal brain parenchyma. In principle, the immune system is uniquely qualified to recognize and target these infiltrative pockets of tumor cells, which have generally eluded conventional treatment approaches. In the span of the last 10 years, our understanding of the cancer-immune system relationship has increased exponentially, and yet, we are only beginning to tease apart the intricacies of the CNS and immune cell interactions. This article reviews the complex associations of the immune system with brain tumors. We provide an overview of currently available treatment options for malignant gliomas, existing gaps in our knowledge of brain tumor immunology, and molecular techniques and targets that might be exploited for improved patient stratification and design of 'custom immunotherapeutics'. We will also examine major new immunotherapy approaches that are being actively investigated to treat patients with malignant glioma, and identify some current and future research priorities in this area.
Yang
Meng-Yin
MY
Division of Neurosurgery, David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA 90095-6901, USA. yangmy04@yahoo.com.tw
Zetler
Paul M
PM
Prins
Robert M
RM
Khan-Farooqi
Haumith
H
Liau
Linda M
LM
D001932:Brain Neoplasms / Q000276:immunology / Q000628:therapy*; D005910:Glioma / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007116:Immunization, Passive / Q000379:methods* / Q000639:trends*